Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. This approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people. It is in contrast to a “one-size-fits-all” approach, in which disease treatment and prevention strategies are developed for the average person, with less consideration of the differences between individuals.
Researchers at WID with expertise in complex biological systems, epigenetics, data science, health care, gene editing, and tissue engineering will contribute to “healthy people” initiatives through precison medicine.
Precision medicine is an important component of WID’s Multi-Omics Hub.
An interdisciplinary pair of WID researchers has developed a new nanocapsule delivery method for delivering the CRISPR-Cas9 gene editing tool. The new system could be used for many types of gene therapies.
WID graduate student Arezoo Movaghar was a collaborator in a study that employed machine learning to mine decades of electronic health records of nearly 20,000 individuals.
Assistant Professor
My research involves the development of statistical models to answer biological questions.
Researchers at the Wisconsin Institute for Discovery are co-Principal Investigators and co-Investigators on four UW2020: WARF Discovery Initiative projects.
WID researchers used a collaborative combination of computational and wet lab experimental techniques to find a connection between a transcription factor and a neurodevelopment gene.
Associate Professor
Neurodevelopmental mechanisms of stress and mental illness in youth
CRISPR-Cas9 Strategy to Generate DOT1L-Deficient Embryonic Stem Cells to Study Pluripotency
WID’s Tom Turng envisions a future in which surgeons can order mass-produced artificial blood vessels that arrive ready to use in bypass surgeries.
WID seeks to add to its roster of excellent faculty with two new hires in emerging cutting-edge fields.
WID’s new hubs—Data Science, Multi-Omics, and Illuminating Discovery—represent a new path forward for collaborative research projects and fields.
A paper published in eLife this week by an interdisciplinary team at WID describes new methods for reproducibly manufacturing brain and spinal cord organoids with strict control over morphogenic and developmental processes.
A second WID-led team joins NIH’s Somatic Cell Genome Editing Consortium with a grant to study new methods of delivering the CRISPR/Cas9 system to the brain.
Lab Manager
Genomic DNA sequencing and viral production. Facilitate various administrative functions.
Investigators from WID are among the recipients of the latest round of UW2020 awards.
Treating ePTFE grafts to mimic the characteristics of human blood vessels.
WID Director
Genetic and biochemical processes underlying interactions within plant and human microbiomes.
One of the UW Carbone Cancer Center members presenting is WID’s Peter Lewis. His work focuses on how genes are turned on and off during embryonic development, and how misregulation in those genes can lead to some childhood cancers.
WID researcher Shaoqin Sarah Gong is working to more safely deliver a variety of drugs to treat cancer, heart disease and even blindness.
Biomedical engineering professor and Discovery Fellow Kristyn Masters and colleagues identified the early stages of a process that may eventually cause aortic stenosis, a severe narrowing of the aortic valve that reduces blood flow to the body and weakens the heart.
In August 2017, Randolph Ashton received almost $800,000 from the National Institute of Neurological Disorders and Stroke, part of NIH, to continue a five-year research study of Lou Gehrig’s disease (amyotrophic lateral sclerosis, or ALS), after successfully completing its first phase.
The National Science Foundation has awarded nearly $20 million to a consortium of universities to support a new engineering research center that will develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Several WID investigators are collaborators on the project.
